In January of this year, the FDA noted that it had "received adverse event reports after patients used compounded semaglutide" and that "patients should not use a compounded drug if an approved drug is available to treat a patient." In July, the agency followed up with a notice that it had "received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products." And in August, Eli Lilly, the maker of Zepbound and Mounjaro, sent a series of cease-and-desist letters to providers urging them to stop prescribing compounded versions of those drugs
For patients who have addressed those two questions - who understand the compounded versus FDA-approved distinction, have confirmed current pricing and terms directly with WellMedr, and want a full-service GLP-1 care model rather than a prescription-and-ship approach - WellMedr is a program worth evaluating through its licensed clinician intake process
Id love to reach 20%, but honestly, Im happy where I am for now
The average cost of Semaglutide GLP-1 typically ranges from $1,000 to $1,500 per month
